Core evidence Clinical impact summary for luliconazole

Outcome measures	Evidence	Implications
Disease-oriented evidence	Clear evidence from in vitro studies and animal models showing significant antidermatophyte activity. In vitro studies also demonstrate good activity against Candida and Malassezia.	Effective therapy for management of tinea corporis/cruris and pedis. Results of trials in onychomycosis awaited. Need for clinical studies in patients with candidiasis.
Patient-oriented evidence	Multiple clinical trials demonstrate efficacy against dermatophytes, even on short-term use. Few drug induced adverse effects.	May be used as one of the first line therapies for treatment of tinea corporis/cruris and tinea pedis. Short course of treatment effective, leading to greater compliance.
Economic evidence	None available currently	–